Serious Injury Law Practice - logo
Serious Injury Law Practice - logo
Personal Injury Lawyers - Serious Law
Spinal Injury Lawyers - Serious Law
Brain & Head Injury Lawyers - Serious Law
Amputation Lawyers - Serious Law
Asbestos Lawyers - Serious Law
Fatal Accident Lawyers - Serious Law
Cerabral Palsy Lawyers - Serious Law
Medical & Clinical Negligence Lawyers - Serious Law
APIL and Personal Injury logos Contact Us
0800 61 66 81
Enquire online Request a brochure Free guideInformation centre
Why choose us? About us Our unique services Substantial awards Our accreditations Key team members Why are services free? The case process Transfer a case to usResource centre
Questions clients ask Enquire online Client case studies Negligence reasons View our testimonials Latest news 08/01/09Free publications
Free DVD Free brochure Free guideSome leukaemia patients who do not respond to conventional treatments may benefit from bone marrow transplants selected to target the cancer directly.
The technique, pioneered in Italy, uses transplants from family members who are not a perfect match.
"Natural killer" cells in the new bone marrow then attack the leukaemia.
Survival rates rose after the treatment, but UK experts say these need to be reproduced on a bigger scale and in different types of the disease.
It's likely to make enormous changes in the practice of transplantation worldwide
Dr Professor Andrea Velardi
University of Perugia
Bone marrow transplantation has been around for half a century, and, in leukaemia, is traditionally given to patients to replace bone marrow destroyed by powerful anti-cancer treatments.
One of the biggest problems in bone marrow transplantation is when the immune cells in the donated bone marrow "reject" their new host.
They launch attacks which can prove fatal in the worst cases, a condition called "graft versus host disease".
To avoid this, patients and donors are carefully screened to produce as perfect a match as possible.
However, some of the most recent research in bone marrow transplantation focuses on using the disease-fighting qualities of bone marrow to destroy cancer cells, either to prevent the disease coming back or to tackle it head-on, even where it is resistant to drugs and other treatments.
Testing for killers
Professor Andrea Velardi, from the University of Perugia in Italy, has been funded by the Anthony Nolan Trust to look for ways to harness these qualities without raising the risk of graft versus host disease.
He has been using donors from the patient's own family who are only a partial match - sharing only 50% of their genetic material.
He found that in some cases, immune cells called "natural killer" cells were active in the donor bone marrow after transplantation, and could launch an effective attack on the leukaemia cells, and that he could predict in advance, using tests, how effective that would be.
In a small group of patients with acute myeloid leukaemia - which makes up approximately a third of all cases - survival rates improved when this kind of transplant was given with the patient already "in remission" - cleared of the disease by chemotherapy.
However, it significantly increased survival - from 2% to 30%, among those patients whose disease had not responded fully to treatment prior to the transplant.
He said: "For patients considered ineligible because of chemo-resistant leukaemia, this is a potentially life-saving advancement.
"It's likely to make enormous changes in the practice of transplantation worldwide."
He said that there were some patients - approximately a third of the population - who could not benefit from the technique, because of a physical makeup which meant that their leukaemia would not respond to the natural killer cells.
In addition, he said, the chances of finding a donor with suitable cells was approximately 50% in the average family size.
Cautious welcome
Other experts welcomed the research, although were cautious about the implications of the findings.
A spokesman for the Leukaemia Research Fund said that, while exciting, more evidence would be needed that the treatment was effective in bigger trials against all types of leukaemia.
In particular, it should be tested on older patients, who make up a large proportion of those whose disease had failed to respond to conventional treatment.
However, he said: "I don't want to underestimate the importance of this work.
"If you are in the position of a patient who has not responded to treatment, the choice between a 2% chance of survival and a 30% chance is not a difficult one."
Professor Velardi's work is due to be presented at a bone marrow transplantation research conference in London next week.
To contact one of our specialist lawyers please call 0800 61 66 81 , or use the contact details at the top left of this page.
"After meeting face to face with our lawyer we understood exactly how you could help us. The way in which you conducted yourselves and attended to all of or needs is a credit to your practice. As you explained, you are different to other law firms an we are glad that we chose you to work for us." Mr D Caswell, Norwich
select this link to see how we can help...Questions answered online within 30 minutes
Specialised lawyer
Answered for free
No commitment
Find out moreHave I got a case?
Working with:
Law Society
Law Society Personal Injury
Association of Personal Injury Lawyers
Headway
Back Up Trust
Motor Accidents Solicitors Society
Investors in People
News centre
Latest News 08/01/09 Surgeons have carried out the first operations in Britain using a pioneering “bionic eye”... Click to read more... Scientists believe they have identified a gene that may be able to limit the growth of breast cancer... Click to read more... All NewsHelp online | FAQs | Site Map | | Contact Us | Privacy Policy | Disclaimer Information | Copyright © 2007. (External) Website development by Athernet Solutions .